Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2000-11-28
2003-06-03
Gitomer, Ralph (Department: 1627)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S021000, C424S569000
Reexamination Certificate
active
06573061
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to methods for the identification of contractile modulators of the cardiac sarcomere and use of such methods for the identification of therapeutic agents.
BACKGROUND OF THE INVENTION
Congestive heart failure is a growing epidemic in our aging population. Its prevalence has been growing as the population ages and as cardiologists are more successful at reducing mortality from ischemic heart disease, the most common cause of congestive heart failure. Roughly 4.6 million people in the United States have heart failure with an incidence approaching 10 per 1000 after age 65 years. Hospital discharges for congestive heart failure rose from 377,000 in 1979 to 957,000 in 1977 making congestive heart failure the most common discharge diagnosis in people age 65 and over. The five year mortality from congestive heart failure approaches 50%. Hospitalization for heart failure is usually the result of inadequate outpatient therapy. Hence, while heart failure therapy has greatly improved over the last several years, new and better therapies are still required to improve these still dismal statistics.
Inotropes are drugs that increase the contractible ability of the heart. As a group, all current inotropes have failed to meet the gold standard for heart failure therapy, that is, to prolong patient survival (FDA Cardiorenal Panel: Minutes Jan. 27, 1998 after session, www.fda.gov). Despite this fact, intravenous inotropes continue to be widely used in acute heart failure to allow for reinstitution of oral medications or to bridge, patients to heart transplantation, whereas in chronic heart failure, oral digoxin in used as an effective inotrope to relieve patient symptoms, improve the quality of life, and reduce hospital admissions for heart failure.
Currently, there is a paucity of agents that can safely improve cardiac function; most agents have detrimental side effects if given for more than a few days. As for chronic inotropic use, only digoxin has proven safe to administer even though it has a narrow therapeutic range. The most recently approved short-term intravenous agent, milrinone, is now over ten years old. The only available oral drug, digoxin, is over 200 hunderd years old. There is a great need for agents that exploit new mechanisms of action and may have better outcomes in terms of relief of symptoms, safety, and patient mortality, both short-term and long-term. The present invention provides methods for identifying such agents.
SUMMARY OF THE INVENTION
The present invention provides methods to identify candidate agents that bind to a protein or act as a modulator of the binding charateristics or biological activity of a protein. In one embodiment, the method is performed in plurality simultaneously. For example, the method can be performed at the same time on multiple assay mixtures in a multi-well screening plate. Furthermore, in a preferred embodiment, fluorescence or absorbance readouts are utilized to determine activity. Thus, in one aspect, the invention provides a high throughput screening system.
In one embodiment, the present inventin provides a method of identifying a candidate agent as a modular of the activity of a target protein complex. Preferably, the target protein complex either directly or indirectly produces ADP or phosphate. More preferably, the target protein complex comprises a preparation comprising one or more of the following proteins: myosin, actin, and cardiac regulatory proteins. In a particularly preferred embodiment, the target protein complex is a reconstituted sarcomere consisting of actin, myosin, and the cardiac regulatory proteins.
The method further comprises adding a candidate agent to a mixture comprising the target protein complex under conditions that normally allow the production of ADP or phosphate. The method further comprises subjecting the mixture to an enzymatic reaction that uses said ADP or phosphate as a substrate under conditions that normally allow the ADP or phosphate to be utilized and determining the level of activity of the enzymatic reaction as a measure of the concentration of ADP or phosphate. The phrase “use ADP or phosphate” means that the ADP or phosphate are directly acted upon. In one case, the ADP, for example, can be hydrolyzed or can be phosphorylated. As another example, the phosphate can be added to another compound. As used herein, in each of these cases, ADP or phosphate is acting as a substrate. A change in the level between the presence and absence of the candidate agent indicates a modular of the target protein complex.
REFERENCES:
patent: 6042855 (2000-03-01), Beitz et al.
patent: 6410254 (2002-06-01), Finer et al.
patent: WO 97/45730 (1997-12-01), None
patent: WO 98/18906 (1998-05-01), None
Haikala H. Tropinin C-Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation. J. of Cardiovascular Pharmacology 25(5)974-801, 1995.*
Margossian S. Preparation of Mysin and Its Subfragments from Rabbit Skeletal Muscle. Methods in Enzymology vol. 85, pp. 55-71, 1982.*
Pollard, et al., “Methods to Characterize Actin Filament Networks”, Methods in Enzymology, vol. 85, pp. 211-233, 1982.
Cooper et al., “Methods to Measure Actin Polymerization”, Methods in Enzymology, vol. 85, pp. 182-210, 1982.
Pollard et al., “The Rate Constant for ATP Hydrolysis by Polymerized Actin”, A.G., FEBS, vol. 170, No. 1, pp. 94-98 May 7, 1984.
Pollard, T.D., “Assays for Myosin”, Methods in Enzymology, vol. 85, pp. 123-130, 1982.
Pollard, T.D., “Purification of Nonmuscle Myosins”, Methods in Enzymology, vol. 85, pp. 331-356, 1982.
Kiehart et al., “Inhibition of acanthamoeba actomyosin-II ATPase activity and mechanochemical function by specific monoclonal antibodies” Journal of Cell Biology, vol. 99, No. 3, pp. 1024-1033, Sep. 1994.
De La Cruz et al., “Transient kinetic analysis of rhodamine phalloidin binding to actin filaments”, Biochemistry, vol. 33, No. 48, pp. 14387-14392, Dec. 6, 1994.
Xu et al., “Mechanical properties of actin filament networks depend on preparation, polymerization conditions, and storage of actin monomers.”, Biophysical Journal, vol. 74, No. 5, pp. 2731-2740, May 1998.
Rock et al., “In vitro assays of processive myosin motors”, J. A., Methods, vol. 22, pp. 373-81, Dec. 2000.
Murphy et al., “The sequence of the myosin 50-20K loop affects Myosin's affinity for actin throughout the actin-myosin ATPase cycle and its maximum ATPase activity”, Biochemistry vol. 38, No. 12 Mar. 23, 1999 pp. 3785-3792.
Goodson et al., “Specialized conservation of surface loops of myosin: evidence that loops are involved in determining functional characteristics”, J Mol Biol, vol. 287, No. 1, Mar. 19, pp. 173-185.
Friedman et al., “Kinetic characterization of myosin head fragments with long-lived myosin ATP states”, Biochemistry, vol. 37, No. 27, Jul. 7, 1998, pp. 9679-9687.
Murphy et al., “Dictyostelium myosin 25-50K loop substitutions specifically affect ADP release rates”, J.A., Biochemistry, vol. 37, No. 19, May 12, 1998, pp. 6738-6744.
Giese, et al. “Phenotypically selected mutations in myosin's actin binding domain demonstrate intermolecular contacts important for motor function”, Biochemistry, vol. 36, No. 28, Jul. 15, 1997, pp. 8465-8473.
Ruppel et al. “Structure-function analysis of the motor domain of myosin”, Annual Rev Cell Dev Biol, vol. 12, 1996, pp. 543-573.
Finer et al. “Characterization of single actin-myosin interactions”, Biophys J, vol. 68, No. 4, Apr. 1995, pp. 291S-296S.
Uyeda et al., “Enzymatic activities correlate with chimaeric substitutions at the actin-binding face of myosin”, Nature, vol. 368, No. 6471, Apr. 7, 1994, pp. 567-569.
Warrick et al., “In vitro methods for measuring force and velocity of the actin-myosin interaction using purified proteins”, Methods Cell Biol, vol. 39, 1993, pp. 1-21.
Uyeda et al., “Assays for actin sliding movement over myosin-coated surfaces” J. A., Methods Enzymol, vol. 196, 1991, pp. 399-416.
Toyoshima et al. “The myosin step size: measurement of the unit displacement per ATP hydrolyzed in an in vitro assay”, P
Finer Jeffrey T.
Hartman James J.
Malik Fady
Sakowicz Roman
Beyer Weaver & Thomas LLP
Cytokinetics Inc.
Gitomer Ralph
Stevens Lauren L.
LandOfFree
Sarcomere protein composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sarcomere protein composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sarcomere protein composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3126406